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Edited by Veli-Pekka LehtoAbstract Fibroblasts are a diverse cell type and display clear
topographic diﬀerentiation and positional memory. In a screen
for ﬁbroblast speciﬁc markers we have characterized four mono-
clonal antibodies to endosialin (TEM1/CD248). Previous studies
have reported that endosialin is a tumour endothelium marker
and is localized intracellularly. We demonstrate conclusively that
endosialin is a cell surface glycoprotein and is predominantly ex-
pressed by ﬁbroblasts and a subset of pericytes associated with
tumour vessels but not by tumour endothelium. These novel anti-
bodies will facilitate the isolation and classiﬁcation of ﬁbroblast
and pericyte lineages as well as the further functional analysis of
endosialin.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Angiogenesis1. Introduction
Fibroblasts are the most abundant cells of the stroma and
are responsible for the synthesis and remodelling of extracellu-
lar matrix components. In addition, their ability to produce
and respond to growth factors allows reciprocal interactions
with other stromal cell types and with adjacent epithelial and
endothelial structures. As well as playing a critical role during
tissue development and homeostasis, ﬁbroblasts also contrib-
ute to the pathology of many diseases either directly for exam-
ple by overproduction of matrix components during ﬁbrosis
and/or indirectly by inﬂuencing the behaviour of neighbouring
cell types [1–5].Abbreviations: TEM, tumour endothelium marker; mAb, monoclonal
antibody; HUVEC, human umbilical vein endothelial cells; SAGE,
serial analysis of gene expression
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doi:10.1016/j.febslet.2005.03.071Despite their importance, ﬁbroblast biology has lagged be-
hind research into other cell types. In part, this reﬂects diﬃcul-
ties in studying a cell type which is phenotypically and
functionally heterogeneous and plastic in its diﬀerentiation
capacity [6,7]. In addition, there are surprisingly few good
selective markers for monitoring and isolating ﬁbroblast pop-
ulations and/or for discriminating between the origins and dif-
ferentiation of ﬁbroblast subtypes. Our approach to this
problem has been to generate a panel of monoclonal antibod-
ies (mAbs) directed against extracellular domain epitopes of
human ﬁbroblast cell surface proteins [8] (see Supplementary
Methods for further details). In this paper, we have used a ser-
ies of further screens to identify mAbs which recognise pro-
teins with a ﬁbroblast-restricted distribution. We describe the
characterization of four novel mAbs directed against a
175 kDa antigen whose expression is restricted to ﬁbroblasts
and which we have identiﬁed as endosialin/tumour endothelial
marker-1 (TEM1/CD248).2. Materials and methods
2.1. Antibodies and cells
The generation of four anti-endosialin mAbs (B1/22, B1/35, B1/473,
18/37) is described in supplementary methods. Aﬃnity puriﬁed anti-
body directed against the D2 domain of NG2 [9] was a gift of W.
Stallcup (The Burnham Institute, La Jolla), mAb 23-C directed
against the Golgi coat protein, bCOP [10] was a gift of K. Willison
(Institute of Cancer Research, London), mAb YRI CD31.12 was a
gift of Ian Bird (Yamanouchi Research Institute, Oxford), anti-
Endo180 mAb E1/183 [11] was directly labelled with Alexa488 using
a Zenon labelling kit (Molecular Probes). The following antibodies
were obtained commercially; FITC conjugated anti-CD31 mAb (clone
WM59; BioLegend), unconjugated and FITC-conjugated anti-CD146
mAb (clone P1H12, Chemicon International), anti-CD90 mAb (clone
AS02, Dianova, Germany), Alexa conjugated second layer antibodies
(Molecular Probes).
Fibroblasts were isolated from synovial tissue, bone marrow, thy-
roid and salivary glands using standard procedures [7]. HUVEC were
isolated from umbilical cords [12] and used between passages 2 and 4.
2.2. Other methods
Details of microscopy, ﬂow cytometry, pulse chase labelling and
mass spectrometry can be found in supplementary information. Proto-
cols for tissue collection were approved by the local ethics committee
LREC number 5735 (Birmingham) and CCR/REC 2042 (London).blished by Elsevier B.V. All rights reserved.
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3.1. A screen for stromal ﬁbroblast cell surface markers
In order to identify ﬁbroblast speciﬁc markers, a panel of
mAbs generated against human ﬁbroblast cell surface proteins
were screened by cell based ELISA and by ﬂow cytometry for
reactivity against primary ﬁbroblasts isolated from rheumatoid
synovium compared to human umbilical vein endothelial cells
(HUVEC). Among the novel mAbs tested, 4 of these (18/37,
B1/473, B1/35, B1/22) were conﬁrmed as reacting strongly
against rheumatoid synovial ﬁbroblasts but not HUVEC
(Fig. 1A). All 4 mAbs were shown to immunoprecipitate a
175 kDa protein from 125I-cell surface labelled ﬁbroblasts
(Fig. 1B) and serial immunoprecipitation and limited proteo-
lytic digestion indicated a common antigen (data not shown).
To further assess the cell type distribution of the p175 antigen,
a large panel of human cell lines were screened either by immu-
noprecipitation or ﬂow cytometry (Fig. 1C). None of the
established lines showed p175 expression including cells of epi-
thelial (A431, MCF7, HEp2, HeLa), neural (1321N1, SK-N-
SH), mesenchymal (MG63, HT1080), haematopoietic (IM9,
CEM, HL60) and endothelial (HUVEC) origin. In contrast,
expression was detected in three diﬀerent human diploid ﬁbro-
blast cultures (AG1523, Flow2000, F1084) and in a wide range
of primary human ﬁbroblasts derived from a variety of sites
(Fig. 2 and data not shown). Although these studies clearly
demonstrated expression of the p175 antigen on primary ﬁbro-
blasts it was important to establish that this did not result from
p175 upregulation when cells were cultured in vitro. To ad-
dress this, cryosections from rheumatoid synovium, tonsil, sal-
ivary gland and breast were stained with mAb B1/35 to labelFig. 1. Identiﬁcation of 4 mAbs directed against a 175 kDa ﬁbroblast cell su
HUVEC were detached from dishes and subject to ﬂow cytometry using 4 an
matched controls (dotted lines) followed by FITC-anti-mouse Ig. As positive
MUC18) were used to label ﬁbroblasts and HUVEC, respectively. The % of c
AG1523 human ﬁbroblasts were cell surface 125I-labelled, lysed and subje
resolved by 10% SDS–PAGE, the gels dried and exposed to X-ray ﬁlm over
mAb 74/3 against the intracellular antigen annexin I [25] were used as positive
(C) Table of cell lines positive or negative for expression of the p175 antige
surface labelling or by ﬂow cytometry. Primary ﬁbroblasts were isolated frop175 expressing cells and with anti-CD31 mAb to label endo-
thelial cells. In all tissues examined, p175+ve cells were re-
stricted to the stromal compartments with no detectable
expression on vasculature or epithelial structures (Fig. 3).
To identify the p175 antigen, Flow2000 human ﬁbroblasts
were lysed and passed over a mAb B1/35 aﬃnity column.
Bound protein was eluted and analysed by mass spectrometry.
Signals observed at m/z 564, 624, 705 and 720 were interpreted
as deriving from the respective sequences V-D-S-L/I-V-G-A-
G. . ., A-L/I-E-A-S..H-R,. . . D-D-P-H-R and . . .Y-A-L/I-F-P-R.
Database searching of these sequences led to an unambiguous
assignment of the 175 kDa antigen as endosialin. To validate
that the anti-p175 mAbs were indeed directed against endosia-
lin, all 4 mAbs were shown to stain COS-1 cells transfected
with the pcDNA3 plasmid containing a human endosialin
cDNA but not cells transfected with a control plasmid
(Fig. 4A).
3.2. Subcellular distribution of endosialin
After cleavage of the N-terminal signal sequence, endosialin
is comprised of a 78.8 kDa protein core modiﬁed by approxi-
mately 95 kDa of highly sialylated O-linked oligosaccharides
[13,14]. Previously, it has been reported that endosialin con-
structs tagged at the C-terminus with either GFP, a Myc epi-
tope or a 6· His epitope were located intracellularly with
only a minor proportion being localized to the plasma mem-
brane [15]. By staining non-permeabilized ﬁbroblasts from a
number of diﬀerent sources (Fig. 2) or by transfecting cells
with a non-tagged endosialin construct (Fig. 4A), we demon-
strate here that both endogenous and exogenous endosialin
are strongly expressed at the cell surface. Further, permeabili-rface protein. (A) Fibroblasts isolated from rheumatoid synovium and
ti-p175 mAbs (18/37, B1/473, B1/35 and B1/22) (solid lines) or isotype-
controls, mAb AS02 (anti-CD90/Thy1) and mAb P1H12 (anti-CD146/
ells labelled with test antibody over controls is shown in each panel. (B)
ct to immunoprecipitation with the 4 anti-p175 mAbs. Lysates were
night. mAb E1/183 against the cell surface receptor Endo180 [11] and
and negative controls, respectively. Molecular size markers are in kDa.
n. Expression was assessed by immunoprecipitation following 125I-cell
m a variety of tissues as shown in Fig. 2.
Fig. 2. Distribution of the p175 antigen on primary human ﬁbroblasts. Fibroblasts isolated from rheumatoid and normal synovium, bone marrow,
labial salivary gland and thyroid were cell surface-stained by incubating for 1 h at 4 C with anti-p175 mAb B1/35. Cells were then ﬁxed,
permeabilized and stained with Alexa555-anti-mouse Ig. HUVEC were stained in parallel and nuclei counterstained with TO-PRO-3 (blue). Scale
bar, 15 lm.
Fig. 3. p175 is expressed by ﬁbroblasts in vivo. Cryosections of human rheumatoid synovium, tonsil, salivary gland and normal breast were stained
with mAb B1/35 to detect p175 (green) and anti-CD31 to label the endothelial cells (red). Sections were counterstained with Hoechst 33258 or TO-
PRO-3 (blue). White arrowheads indicate endosialinve epithelial cells in the salivary gland and breast lobular unit. Yellow arrowheads indicate
endosialinve lymphocyte aggregates in perivascular cuﬀs of rheumatoid synovium and tonsil. Scale bar, 50 lm.
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intracellular perinuclear staining in a small proportion of cells.
Double labelling revealed that this intracellular pool of endosi-alin co-localises with the Golgi network but not with markers
of endosomes (Fig. 4B), endoplasmic reticulum or lysosomes
(data not shown). Consistent with this staining data, pulse
Fig. 4. The p175 antigen is endosialin. (A) COS-1 cells were transfected with pcDNA3-endosialin (see Supplementary Methods for construct design)
or pcDNA3-Endo180 [26]. After 48 h, cells were ﬁxed, permeabilized and stained with anti-p175 mAbs B1/35, B1/473, B1/22 or 18/37 followed by
Alexa555-anti-mouse Ig and nuclei counterstained with TO-PRO-3. (B) MG63 cells transiently transfected with pcDNA3-endosialin were
permeabilized and double-stained with mAb B1/35 followed by Alexa555-anti-mouse Ig (red) and either Alexa488 labelled anti-Endo180 mAb E1/183
to label endosomes or the anti-bCOP mAb 23-C followed by Alexa488-anti-rat Ig to label the Golgi apparatus (green). Control cells were transfected
with pcDNA3 vector alone and labelled in parallel with mAb B1/35 followed by Alexa555-anti-mouse Ig. Nuclei were counterstained with TO-PRO-
3 (blue). Scale bar, 20 lm.
Fig. 5. Biosynthesis of endosialin. Flow2000 human ﬁbroblasts were
labelled for 15 min with 35S-methionine and then chased for 0–48 h in
medium without 35S-methionine. At indicated times, cells were lysed
and immunoprecipitated with mAb B1/473. Immunoprecipitates were
resolved by 7% SDS–PAGE and exposed to X-ray ﬁlm overnight.
Molecular size markers are in kDa.
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labelling, a single immaturely glycosylated form of endosialin
is observed which within 1 h of chase is converted into the ma-ture 175 kDa form, a process that is complete within 2 h. The
mature form of endosialin has a relatively short half life of
approximately 3–4 h (Fig. 5). Together these data indicate that
at steady state, a small proportion of endosialin will be local-
ized to the intracellular secretory machinery and in particular
in the Golgi apparatus which is the site for addition and mod-
iﬁcation of O-linked oligosaccharides. Further, we suggest that
the reason for the discrepancy between the data presented here
and previous reports [15] is that the presence of a C-terminal
tag and/or overexpression of exogenous endosialin in the
transfected cells resulted in aberrant accumulation of this
heavily O-glycosylated transmembrane protein in intracellular
secretory organelles. An alternative possibility is that the
mAbs employed in our study recognise a variant epitope which
is preferentially revealed at the cell surface. We consider this
unlikely given that the 4 mAbs employed here all recognise
both immature and mature forms of endosialin in pulse chase
experiments and yet do not share a common epitope (data not
shown).
3.3. Endosialin is not expressed by normal or angiogenic
endothelium
As described above, our in vitro studies indicated that
endosialin is highly restricted in its distribution to ﬁbroblasts
and is not expressed on resting HUVEC or on endothelial cells
in sections of inﬂamed and normal tissue. This observation is
at variance with previous studies. First, in a serial analysis of
gene expression (SAGE) screen of endothelial cells isolated
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the most highly upregulated transcript in tumour endothelium
compared to normal endothelium hence its alternate name of
TEM1 [16]. Second, by immunohistochemistry it has been re-
ported that endosialin is expressed on angiogenic endothelial
cells but not normal tissue endothelium [13,17]. To determine
whether the lack of endosialin expression in HUVEC reﬂected
their unstimulated status, cells were stimulated with the pro-
angiogenic/inﬂammatory factors TNF-a, TGF-b2 and IL-1.
These treatments did not result in upregulation of endosialin
expression (Fig. 6). However, it remained a possibility that
stimulated HUVEC did not provide a suitable model for the
in vivo microenvironment of tumour endothelial cells.Fig. 6. Endosialin is not expressed by resting or activated HUVEC. HUVEC
ml) or IL-1 (1 ng/ml). Cells were detached from tissue culture dishes with ED
Fig. 7. Endosialin expression in breast tumours. (A) Three diﬀerent breast tu
(mAb B1/35; green). Nuclei were counterstained with DAPI (blue). (B, C) H
breast tumour triple labelled for CD31, endosialin and NG2 with nuclei c
combinations; CD31 alone (red); CD31 (red) and endosialin (green); CD31 (
endosialinve pericytes. Scale bar, 50 lm.To address these discrepancies more directly, sections from
breast tumours were stained for endosialin in conjunction with
the pan-endothelial marker CD31. In all sections examined,
endosialin staining was observed on stromal ﬁbroblasts
although it was notable that ﬁbroblast expression was highly
variable between the diﬀerent tumours. In addition, in compar-
ison to normal breast tissue (see Fig. 3) endosialin staining was
observed on a subset of the tumour vasculature and this was
particularly prominent in tumours where endosialin expression
in the stromal compartment was low (Fig. 7A). However, clo-
ser examination of these sections strongly indicated that
endosialin expression in the vasculature was restricted to peri-
vascular cells intimately associated with the endothelial cellswere treated in culture for 24 h with TNFa (10 ng/ml), TGF-b2 (2 ng/
TA and analysed as described in Fig. 1A.
mours showing expression of CD31 (mAb WM59; red) and endosialin
igher magniﬁcation images showing a section of normal breast and a
ounterstained with DAPI (blue). Images are shown in the following
red) and NG2 (green). Arrowheads in normal breast indicate NG2+ve/
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observations and further characterize this perivascular expres-
sion, sections of normal breast and breast tumours were la-
belled for endosialin, CD31 and the pericyte marker NG2
[18,19]. In all tumour sections examined, but not in normal
breast tissue, there was colocalization of endosialin and NG2
expression in the perivascular cells (Fig. 7B and C) indicating
that the endosialin+ve perivascular cells are pericytes and that
expression is increased in pericytes associated with angiogenic
compared to normal vessels.
These observations raised the issue as to whether the
endothelial cells isolated by magnetic bead immunopuriﬁca-
tion with the anti-CD146 mAb P1H12 for the SAGE screen
[16] were contaminated with non-endothelial perivascular
cells which expressed CD146 or remained tightly adherent
to the CD146+ve endothelial cells during the isolation proce-
dure. To address this, breast and colorectal tumour sections
were double labelled for CD31 and CD146 (Fig. 8). In all
sections examined, strong colocalization of CD146 with all
CD31+ve cells was observed. However, in addition, CD146
was also clearly expressed by CD31ve perivascular cells
which were closely associated with the angiogenic endothelial
cells.
These data together indicate the following: (a) CD146, as
detected by mAb P1H12, is not an endothelial speciﬁc mar-
ker but is also expressed by non-endothelial perivascular
cells. It should be noted that CD146 has previously been re-
ported to be expressed not only by small and large vessel
endothelial cells but also expressed by breast epithelial cells,
smooth muscle cells, myoﬁbroblasts and melanoma cells [20],
(b) although expressed on a subset of tumour vasculature,
endosialin is not expressed by tumour endothelium. We sug-
gest that the identiﬁcation of endosialin as a transcriptFig. 8. CD146 is expressed by CD31+ve endothelial cells as well as CD31ve p
(A) or breast carcinoma (B) were stained with anti-CD31 mAb YRI and A
(green). Nuclei were counterstained with TO-PRO-3 (blue). Scale bar, 50 lmhighly upregulated in angiogenic endothelium results from
the contamination of the endosialinve/CD146+ve endothelial
population with endosialin+ve/CD146+ve perivascular cells
and/or closely associated endosialin+ve/CD146ve ﬁbroblasts.
Similarly, we would suggest that in situ hybridization and
immunohistochemistry [13,21] cannot be used to identify
endothelial speciﬁc markers without employing double label-
ling methods to visualise closely apposed ﬁbroblasts and per-
ivascular cells, and (c) the endosialin+ve perivascular cells
also express NG2 suggesting that they are pericytes. Peri-
cytes and other mural cells modulate the physiology of the
vessels, are functionally co-dependent on the endothelial
cells, are highly variable between diﬀerent tissues and or-
gans, and have been implicated in a number of disease pro-
cesses including tumour angiogenesis [22–24]. Further,
pericytes are notably plastic in their phenotype and the
expression of endosialin in a subset of these cells suggests
either that they have been recruited from the stromal ﬁbro-
blast population and/or that they are undergoing ﬁbroblast
diﬀerentiation.
In conclusion, previous discussion as to the function of
endosialin has focussed on its role in tumour angiogenesis
and its reported intracellular distribution. The data presented
here contradicts these assertions and instead we propose that
endosialin is predominantly restricted to ﬁbroblasts where it
is likely to function as a plasma membrane receptor to bind
extracellular ligands. In addition, although we have demon-
strated that endosialin is not a TEM, it is of great interest that
its expression is upregulated on pericytes in tumour but not
normal tissue. Consequently, it will be important to investigate
whether endosialin plays a role in tumour angiogenesis by
modulating the behaviour of pericytes and surrounding stro-
mal ﬁbroblasts.erivascular stromal cells. Cryosections of human colorectal carcinoma
lexa555-anti-rat Ig (red) followed by FITC-anti-CD146 mAb P1H12
.
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